Cognitive Research

“Cognitive research” peptides are a loosely defined category of research compounds studied for their effects on learning, memory, attention, and stress-related behavior in laboratory models — and Semax and Selank are the two compounds most often used to represent it. Both are short synthetic peptides derived from naturally occurring human regulatory molecules, both appear in published work on brain-derived neurotrophic factor (BDNF), and both have been characterized largely by a small number of research groups in Russia. They are not the same compound, they were developed from different parent molecules, and their documented mechanisms diverge. This overview describes what defines the category, what published research models actually show for each peptide, how the two relate as research tools, and — importantly — the limits of that evidence, which is preclinical-dominated and, on the human side, narrow and not independently replicated.

What defines the cognitive-research category

The phrase “cognitive research” is a descriptive grouping, not a regulatory or pharmacological class. It refers to peptides that have been studied in models relevant to cognition: tasks measuring learning and memory in rodents, electrophysiological measurements of synaptic activity, gene- and protein-expression studies of neurotrophic and inflammatory signaling, and — in a smaller body of work — behavioral models of stress and anxiety-related behavior. What the compounds in this grouping tend to share is an apparent influence on neurotrophin signaling, particularly BDNF, the protein most consistently linked in neuroscience to synaptic plasticity and the cellular processes underlying learning.

It is worth being precise about what that grouping does and does not imply. Placing Semax and Selank in a “cognitive research” category says that they have been studied in cognition-relevant model systems. It does not say that they improve cognition in humans, that they are interchangeable, or that they act through the same pathway. As the sections below show, the mechanistic literature pulls them in partly different directions: Semax is studied most heavily in the context of neurotrophin expression and cerebral-ischemia models, while Selank’s research extends into GABAergic synaptic activity, anxiety-related behavioral models, and immune-related gene expression. The category is a starting point for organizing the literature, not a claim of equivalence.

One characteristic defines the category as much as any mechanism: the shape of its evidence base. The Semax and Selank literature is heavily Russian-published and dominated by animal and molecular studies. Human studies exist but are small, Russian-published, and have not been independently replicated by research groups elsewhere. Any honest treatment of this category has to foreground that fact rather than bury it, because it determines how much weight the findings can bear.

Semax: what it is

Semax is a synthetic heptapeptide — a chain of seven amino acids — structurally based on a fragment of adrenocorticotropic hormone, the ACTH(4–10) sequence, extended with a Pro-Gly-Pro tail that improves its stability. The parent fragment itself has no hormonal (corticotropic) activity of its own; the design intent behind Semax was to retain sequence-related effects on the nervous system while removing the hormonal action. In the research-supply context it is produced synthetically and handled as a research chemical. Much of the published primary research administers it intranasally in rodents, which is the route most commonly seen when reading the literature.

Semax: documented mechanisms

The most developed mechanistic thread in the Semax literature concerns BDNF and related neurotrophins. Work in rats reported that Semax regulates the expression of BDNF and its receptor trkB in the hippocampus, with a single dose associated with an increase in hippocampal BDNF protein of roughly 1.4-fold, enhanced trkB activation, and improved performance on a conditioned-avoidance learning task.¹ A companion study reported that Semax binds specifically to membranes from the rat basal forebrain in a calcium-dependent manner and raised BDNF protein levels there after intranasal administration, which provided a candidate point of molecular interaction for the peptide.² Earlier in vivo work had already reported that intranasal Semax increased BDNF expression across several brain regions rather than in a single area.³

That regional picture was refined by expression studies examining timing. One study comparing the dynamics of nerve growth factor (NGF) and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax reported region-specific, time-dependent activation of both neurotrophin genes — in other words, the effect on transcription is not uniform but varies by brain area and by time after dosing.⁴ The through-line across this body of work is consistent: Semax is studied as a compound that influences neurotrophin and neurotrophin-receptor expression, with BDNF the most frequently measured endpoint.

A second major thread concerns cerebral ischemia — reduced blood flow to the brain, the laboratory model of stroke. In a rat model of cerebral ischemia, Semax (together with the Pro-Gly-Pro fragment) was reported to selectively activate the transcription of neurotrophins and their receptor genes in the cortex, linking the neurotrophin mechanism to an injury context.⁵ A genome-wide transcriptional analysis of rat brain after focal ischemia reported that, among all the gene programs Semax affected, the immune response was the most strongly modulated, with vascular-development genes also affected — a broader picture than neurotrophins alone.⁶ A later proteomic study in a rat ischemia-reperfusion model reported that Semax suppressed inflammatory markers including MMP-9, c-Fos, and JNK while activating the CREB signaling pathway.⁷ An earlier study reported that Semax, unlike glycine, abated the rise in nitric-oxide generation in the cerebral cortex of rats subjected to incomplete global ischemia and was associated with improved neurologic function.⁸ Taken together, these studies position Semax in the research literature as a compound studied for neurotrophin regulation and for anti-inflammatory and neuroprotection research in rodent models of ischemic brain injury.

Semax: research models

The model systems that define the Semax literature are, in order of prominence: rodent gene- and protein-expression studies of BDNF and other neurotrophins; rodent cerebral-ischemia models (both focal, such as middle-cerebral-artery occlusion, and global ischemia); and a smaller set of behavioral learning tasks such as conditioned avoidance. On the human side, the published evidence is limited to Russian clinical studies. One such study examined Semax in patients at different stages of ischemic stroke and reported raised plasma BDNF and accelerated motor and functional recovery.⁹ That study should be read for exactly what it is: a Russian-published clinical report that has not been independently replicated by research groups elsewhere. It is consistent with the rodent neurotrophin and ischemia work, but a single regionally concentrated literature is not the same as a replicated international evidence base, and the finding does not establish that Semax treats, cures, or prevents stroke or any other condition. A fuller treatment of the compound on its own is on the dedicated Semax research page.

Selank: what it is

Selank is a synthetic peptide based on tuftsin, a short naturally occurring immunomodulatory peptide that is itself a fragment of the immunoglobulin G heavy chain. As with Semax, a Pro-Gly-Pro-type extension was added to the parent sequence to improve stability. The tuftsin lineage is the reason Selank’s research reaches into immune-related endpoints as well as cognition- and stress-related ones — the parent molecule’s defining role is immunological. Selank is produced synthetically for laboratory research and, like Semax, is most often administered intranasally in the published rodent work.

Selank: documented mechanisms

Selank’s mechanistic literature has three main strands. The first, shared with Semax, is BDNF. Intranasal Selank was reported to regulate BDNF expression in the rat hippocampus in vivo.¹⁰ A later behavioral study reported that Selank protected against ethanol-induced memory impairment in rats and linked its cognitive-stimulating effect to BDNF content in the hippocampus and prefrontal cortex.¹¹ So Selank, like Semax, appears in the BDNF literature — but it reaches that endpoint within a different overall mechanistic picture.

The second strand is GABAergic and inhibitory synaptic activity. A brain-slice electrophysiology study reported that Selank increased both the amplitude and the frequency of inhibitory postsynaptic currents in hippocampal CA1 pyramidal neurons — a direct, measured effect on inhibitory synaptic transmission.¹² A separate in vitro study using a human IMR-32 cell line examined the expression of genes involved in GABAergic neurotransmission and reported that Selank on its own had little effect on those genes, showing a modulatory effect mainly in combination with other agents.¹³ The honest reading of these two studies together is that a GABAergic mechanistic link for Selank is suggested by the electrophysiology but is incompletely characterized at the gene-expression level — it is an open mechanistic question, not a settled one.

The third strand is immune-related gene expression, the strand most clearly traceable to the tuftsin parent. A study of the temporal dynamics of inflammation-related gene expression reported that Selank and its Gly-Pro fragment altered the messenger-RNA levels of immune and inflammation genes — including C3, Casp1, Il2rg, and Xcr1 — in rat spleen.¹⁴ This places part of Selank’s documented activity outside the brain entirely, in peripheral immune tissue, and is a reason the compound is not described purely as a cognition-research peptide.

Selank: research models

Beyond the BDNF, electrophysiology, and immune-gene work above, Selank is most associated with anxiety-related behavioral models in rodents. One study reported that Selank reduced anxiety-related behavior on its own in rats and enhanced the anxiety-modulating effect of a benzodiazepine under an unpredictable chronic-mild-stress paradigm.¹⁶ It is important to describe this accurately: these are anxiety-related behavioral models in rodents, not demonstrations that Selank treats anxiety as a clinical condition. On the human side, the evidence is again limited to Russian clinical reports. One such study compared Selank with a benzodiazepine in patients with anxiety disorders and reported an anxiety-modulating effect with a favorable tolerability profile and mild cognitive effects that persisted about a week after treatment ended.¹⁵ As with the Semax human data, this is a small, Russian-published clinical study that has not been independently replicated, and it does not establish that Selank treats, cures, or prevents any condition. The dedicated Selank research page covers the compound in more depth.

How Semax and Selank relate as research tools

The two compounds are best understood as related but distinct research tools rather than as variants of one thing. Their similarities are real: both are short synthetic peptides derived from naturally occurring human regulatory molecules; both carry a Pro-Gly-Pro-type stabilizing extension; both are most often dosed intranasally in published rodent work; and both appear in the BDNF literature, which is the main reason they are grouped together in a cognitive-research category at all.

Their differences are equally real and follow from their parent molecules. Semax descends from an ACTH fragment, and its research is concentrated on neurotrophin expression and on cerebral-ischemia and neuroprotection models. Selank descends from tuftsin, an immune peptide, and its research spans GABAergic and inhibitory synaptic activity, anxiety-related behavioral models, and peripheral immune-gene expression in addition to BDNF. A research protocol interested in neurotrophin regulation in an ischemia model has a different rationale for selecting Semax; a protocol interested in inhibitory synaptic transmission or in anxiety-related behavioral models has a different rationale for selecting Selank. The choice follows the mechanism under investigation, not a ranking of one peptide as universally “stronger.” A more detailed side-by-side treatment is in our Semax vs Selank comparison.

One further point matters for anyone reading across the two literatures: direct head-to-head studies of Semax and Selank in the same model are uncommon, so most comparison is an inference across separate bodies of work rather than a reading of a single controlled experiment. That is a limitation of the published record, not a gap that a confident summary can paper over.

The shared evidence picture

This is the most important section of any honest category overview, because it is where enthusiasm most often outruns data. For both Semax and Selank, the evidence base shares the same overall shape, and stating that shape plainly matters more than any individual finding above.

First, the literature is predominantly preclinical. The great majority of the studies cited here are animal (rodent) or in vitro — gene-expression analyses, protein measurements, brain-slice electrophysiology, and behavioral tasks. Preclinical findings of this kind establish biological plausibility and identify mechanisms worth studying; they do not establish that an effect will occur, or be beneficial, in a human, or in any specific application.

Second, the literature is geographically concentrated. Semax and Selank were developed and have been characterized largely by a small number of research groups in Russia, and most primary studies — including the human studies — are Russian-published. That is not in itself a criticism of the work, but it is a structural feature that limits how much weight the findings can bear. Independent replication by research groups in other countries is how scientific findings become robust, and for these two compounds that independent, large-scale replication has not happened.

Third, the human evidence is small and preliminary. For Semax, the human data are confined to Russian clinical studies in ischemic-stroke patients. For Selank, they are confined to small Russian clinical reports in anxiety disorders. None of these have been independently replicated internationally, and none constitute the kind of large randomized controlled efficacy trial that would be needed to establish a clinical effect. The accurate way to treat the human findings is as preliminary signals consistent with the preclinical mechanisms — not as established conclusions.

So the accurate summary of the cognitive-research category, as represented by Semax and Selank, is this: these are research compounds whose effects on neurotrophin signaling, synaptic activity, immune-related gene expression, and behavior in stress and learning models are documented in animal and in vitro work, with limited and not-independently-replicated human data. Any claim that either compound improves cognition, reduces anxiety, or aids recovery in humans goes beyond what the published record currently supports.

What this does not mean

This article is an educational overview of a research-compound category at the level of documented mechanism and published model systems. It is not medical, veterinary, or scientific advice, and nothing here describes or recommends use in humans or animals. The studies cited are preclinical except where a Russian-published human clinical study is explicitly identified, and a small, non-replicated clinical report is not evidence of established efficacy. Describing Selank’s appearance in “anxiety-related behavioral models in rodents” is a description of a laboratory model; it is not a statement that Selank treats anxiety, and the same caution applies to every endpoint discussed here. Semax and Selank are sold strictly as research chemicals for in-vitro laboratory research. They are not drugs, supplements, or foods; they are not approved for human or animal use; and they are not intended to diagnose, treat, cure, or prevent any condition.

Frequently asked questions

What is the “cognitive research” peptide category?

It is a descriptive grouping, not a regulatory or pharmacological class. It refers to research compounds — here, Semax and Selank — that have been studied in laboratory models relevant to learning, memory, attention, and stress-related behavior. Grouping them this way says they have been studied in cognition-relevant models; it does not say they improve cognition in humans or that they are interchangeable.

Are Semax and Selank the same kind of peptide?

No. Both are short synthetic peptides with a Pro-Gly-Pro-type stabilizing extension, and both appear in the BDNF literature, which is why they are grouped together. But Semax is derived from an ACTH(4–10) fragment and Selank is derived from tuftsin, an immune peptide. They have different parent molecules and partly different documented mechanisms.

What does the research say about Semax’s mechanism?

The Semax literature centers on neurotrophin signaling — particularly BDNF and its receptor trkB — and on rodent cerebral-ischemia models, where studies report neurotrophin gene activation, suppression of inflammatory markers, and reduced ischemia-related nitric-oxide generation. These are preclinical findings in animal and in vitro models.

What does the research say about Selank’s mechanism?

Selank’s documented research spans three strands: BDNF expression in the hippocampus and prefrontal cortex; GABAergic and inhibitory synaptic activity, where a brain-slice study reported increased inhibitory postsynaptic currents; and immune-related gene expression in peripheral tissue, traceable to its tuftsin parent. The GABAergic link is suggested by electrophysiology but is incompletely characterized.

Is there human research on Semax or Selank?

Limited human data exist for both, but it is confined to small Russian-published clinical studies — for Semax, in ischemic-stroke patients; for Selank, in anxiety disorders. These studies have not been independently replicated by research groups elsewhere and do not constitute large randomized controlled efficacy trials. They should be read as preliminary signals, not established conclusions.

Why is so much of this literature Russian-published?

Semax and Selank were developed and have been characterized largely by a small number of research groups in Russia, so most primary studies — including the human ones — are Russian-published. This is a structural feature of the evidence base. Independent replication by groups in other countries is how findings become robust, and for these two compounds that independent large-scale replication has not happened.

Does the research show these compounds improve cognition or reduce anxiety in people?

No. The published research documents effects on neurotrophin signaling, synaptic activity, immune-related gene expression, and behavior in animal and in vitro models, plus limited non-replicated human data. It does not establish that either compound improves cognition, reduces anxiety, or aids recovery in humans. Anxiety-related rodent behavioral models are laboratory tools, not demonstrations of treatment.

What should a laboratory check before sourcing either compound?

Identity and purity, documented on a batch-specific Certificate of Analysis: an HPLC purity result with a chromatogram and a mass-spectrometry result confirming molecular identity, both tied to the lot number on the vial. Our guide on how to read a peptide COA walks through each section.

References

Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006. PMID 16996037
Dolotov OV, et al. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006. PMID 16635254
Dolotov OV, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Dokl Biol Sci. 2003. PMID 14556513
Shadrina M, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010. PMID 19662538
Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010. PMID 19633950
Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014. PMID 24661604
Sudarkina OY, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021. PMID 34201112
Bashkatova VG, et al. Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Res. 2001. PMID 11245825
Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID 29798983
Inozemtseva LS, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008. PMID 18841804
Kolik LG, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019. PMID 31625062
Povarov IS, et al. Effect of Selank on spontaneous synaptic activity of rat hippocampal CA1 neurons. Bull Exp Biol Med. 2017. PMID 28361410
Filatova E, et al. GABA, selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017. PMID 28293190
Kolomin T, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014. PMID 24291245
Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID 25176261
Kasian A, et al. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behav Neurol. 2017. PMID 28280289

Continue

Research Use Only. This page is an educational research overview for laboratory and scientific context, and is not medical advice. The compounds described are sold strictly as research chemicals for in-vitro laboratory research. They are not drugs, supplements, or foods, and are not intended for human or animal consumption, diagnosis, treatment, or to prevent any condition.